共 27 条
Treatment of neurological injury with thymosin β4
被引:19
作者:
Morris, Daniel C.
[1
]
Zhang, Zheng G.
[2
]
Zhang, Jing
[2
]
Xiong, Ye
[3
]
Zhang, Li
[2
]
Chopp, Michael
[2
,4
]
机构:
[1] Henry Ford Hlth Sci Ctr, Dept Emergency Med, Detroit, MI USA
[2] Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA
[3] Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA
[4] Oakland Univ, Dept Phys, Rochester, MI USA
来源:
THYMOSINS IN HEALTH AND DISEASE I
|
2012年
/
1269卷
关键词:
thymosin beta 4;
stroke;
multiple sclerosis;
traumatic brain injury;
rat;
TRAUMATIC BRAIN-INJURY;
MULTIPLE-SCLEROSIS;
ANIMAL-MODELS;
RAT MODEL;
STROKE;
REMYELINATION;
NEUROGENESIS;
PRECURSORS;
ISCHEMIA;
RECOVERY;
D O I:
10.1111/j.1749-6632.2012.06651.x
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Neurorestorative therapy targets multiple types of parenchymal cells in the intact tissue of injured brain tissue to increase neurogenesis, angiogenesis, oligodendrogenesis, and axonal remodeling during recovery from neurological injury. In our laboratory, we tested thymosin beta 4 (T beta 4) as a neurorestorative agent to treat models of neurological injury. This review discusses our results demonstrating that T beta 4 improves neurological functional outcome in a rat model of embolic stroke, a mouse model of multiple sclerosis, and a rat model of traumatic brain injury. T beta 4 is a pleiotropic peptide exhibiting many actions in several different types of tissues. One mechanism associated with improvement of neurological improvement from T beta 4 treatment is oligodendrogenesis involving the differentiation of oligodendrocyte progenitor cells to mature myelin-secreting oligodendrocytes. Moreover, our preclinical data provide a basis for movement of T beta 4 into clinical trials for treatment of these devastating neurological diseases and injuries.
引用
收藏
页码:110 / 116
页数:7
相关论文